<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01142908</url>
  </required_header>
  <id_info>
    <org_study_id>IIR 08-297</org_study_id>
    <nct_id>NCT01142908</nct_id>
  </id_info>
  <brief_title>Cardiovascular Intervention Improvement Telemedicine Study</brief_title>
  <official_title>Cardiovascular Intervention Improvement Telemedicine Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular disease (CVD) is the leading cause of death in the United States; more than
      80% of veterans have &gt; 2 risk factors for CVD. Our study is one of the first to examine the
      implementation of a tailored behavioral/educational self-management intervention in primary
      care clinics designed to improve CVD risk. The proposed study could result in a leap forward
      in CVD risk management among veterans for several reasons: 1) ) This is a novel extension of
      our previous interventions that have demonstrated improved BP, now designed to address
      multiple chronic conditions contributing to CVD risk, particularly hyperlipidemia and
      diabetes. The study focuses on both multiple CVD-related risk factor management and
      medication management 2) The intervention is multi-behavioral; it addresses patients' various
      health behavior (e.g., smoking, diet, and medication adherence). 3) Components of the
      intervention will include specific recommendations and transportability of intervention
      application software and tracking packages that will allow clinic managers to implement the
      intervention if it is effective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anticipated Impacts on Veteran's Healthcare: Cardiovascular disease (CVD) is the leading
      cause of death in the U.S.; more than 80% of veterans have &gt; 2 risk factors for CVD. An
      intervention that addresses multiple CVD risk factors among high-risk veterans has the
      greatest potential to improve morbidity and mortality.

      Project Background/Rationale: The proposed study will take place in two VA primary care
      clinics (1-Community-Based Outpatient Clinics and 1-primary care clinic affiliated with a
      hospital). We will improve CVD risk among veterans by addressing the modifiable risk factors
      of systolic blood pressure (SBP), smoking, and low-density lipoprotein cholesterol (LDL-C).
      The intervention will be tailored to the needs of vulnerable high risk patients (e.g. African
      Americans, low literate) and integrated into clinics, thereby enhancing the potential for
      benefit and generalizability to other settings.

      The proposed study could significantly improve CVD risk management among veterans for several
      reasons: 1) This intervention is a novel extension of our previous efficacious interventions,
      but provides a novel extension to address multiple chronic conditions contributing to CVD
      risk. 2) The intervention focuses on both multiple CVD-related behaviors and medication
      management. 3) The intervention was developed to ensure implementation across a large and
      representative sample of veterans; and; 4) The intervention, if found efficacious and
      financially self-sustaining, could be widely implemented within the VA healthcare system.

      Project Objectives: The proposed study will examine two research questions:

        1. Can patients randomized to a clinical pharmacist-administered telephone behavioral/
           medication management intervention tailored to their needs improve CVD outcomes relative
           to a control group over 12 months? Primary Hypothesis: (H1) Veterans who receive the
           behavioral/medication intervention will have greater improvement of their CVD Risk
           Profile over the 12 months of follow-up as compared to the control group.

           Secondary Hypotheses: (H2) Veterans who receive the intervention will have improved
           medication adherence, physical activity, improved diet, lower body mass index as
           compared to the control group over 12 months of follow-up. (H3) Veterans who receive the
           intervention will have greater improvements in LDL over the 12 months of follow-up as
           compared to the control group. (H4) Veterans with diabetes who receive the intervention
           will have greater improved HbA1c as compared to the control group over 12 months of
           follow-up.

        2. If the intervention is found to be effective, is it cost effective? Project Methods: To
           address these hypotheses, we propose a two-arm randomized clinical trial design in which
           500 patients with cardiovascular disease will be randomized to either the education
           control group or the intervention group. Patients randomized to the intervention group
           will receive a clinical pharmacist-administered intervention, which focuses on
           behavioral and a medication management. The intervention will occur over 12 months.
           Patients randomized to the control group will receive educational material about CVD
           reduction. Given the national prevalence of CVD and the dismal rates of risk factor
           control, intensive, but easily disseminated interventions such as the one proposed could
           significantly improve treatment of this epidemic in the VA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)</measure>
    <time_frame>Baseline</time_frame>
    <description>Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and VA Computerized Patient Record System (CPRS) data review). &quot;New cases&quot; of diabetes are allowed to be updated at 6 and 12 months f/u.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)</measure>
    <time_frame>6 months</time_frame>
    <description>Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and CPRS data review). &quot;New cases&quot; of diabetes are allowed to be updated at 6 and 12 months f/u.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)</measure>
    <time_frame>12 months</time_frame>
    <description>Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and CPRS data review). &quot;New cases&quot; of diabetes are allowed to be updated at 6 and 12 months f/u.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Systolic Blood Pressure</measure>
    <time_frame>Baseline</time_frame>
    <description>Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Systolic Blood Pressure</measure>
    <time_frame>6 months</time_frame>
    <description>Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Systolic Blood Pressure</measure>
    <time_frame>12 months</time_frame>
    <description>Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Diastolic Blood Pressure</measure>
    <time_frame>Baseline</time_frame>
    <description>Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Diastolic Blood Pressure</measure>
    <time_frame>6 months</time_frame>
    <description>Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Diastolic Blood Pressure</measure>
    <time_frame>12 months</time_frame>
    <description>Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Non-adherence</measure>
    <time_frame>Baseline</time_frame>
    <description>First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Non-adherence</measure>
    <time_frame>6 months</time_frame>
    <description>First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Non-adherence</measure>
    <time_frame>12 months</time_frame>
    <description>First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol LDL</measure>
    <time_frame>Baseline</time_frame>
    <description>Collected during interview visit by lab personnel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol LDL</measure>
    <time_frame>6 months</time_frame>
    <description>Collected during interview visit by lab personnel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol LDL</measure>
    <time_frame>12 months</time_frame>
    <description>Collected during interview visit by lab personnel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>Baseline</time_frame>
    <description>Calculated from vitals (height &amp; weight) obtained during interview</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>6 months</time_frame>
    <description>Calculated from vitals (height &amp; weight) obtained during interview</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>12 months</time_frame>
    <description>Calculated from vitals (height &amp; weight) obtained during interview</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBA1C in Diabetic Patients</measure>
    <time_frame>Baseline</time_frame>
    <description>Lab values collected at interview visit by lab personnel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBA1C in Diabetic Patients</measure>
    <time_frame>6 months</time_frame>
    <description>Lab values collected at interview visit by lab personnel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBA1C in Diabetic Patients</measure>
    <time_frame>12 months</time_frame>
    <description>Lab values collected at interview visit by lab personnel</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">428</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Hypertension</condition>
  <condition>Diabetes</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The education control group - these participants will receive educational material about CVD reduction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Pharmacist CVD</intervention_name>
    <description>clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enrolled in one of three Durham Veterans Affairs Medical Center (DVAMC) Primary Care
             Clinics affiliated with the hospital or the Raleigh Community-Based Outpatient Clinic
             (CBOC) for at least one year;

          -  At least one visit to a primary care physician (PCP) at the Raleigh CBOC or Durham
             Veterans Affairs Medical Center (VAMC) associated primary care clinics in the previous
             12 months;

          -  Outpatient diagnostic code for hypertension and/or hypercholesterolemia and lab values
             indicating either poorly controlled BP levels (&gt;150/90 Hg) AND/OR LDL (&gt;130mg/dl) in
             the previous year.

        Exclusion Criteria:

          -  diagnosed with metastatic cancer,

          -  diagnosed with dementia,

          -  active diagnosis of psychosis,

          -  treated with dialysis,

          -  most recent creatinine lab level &gt;2.5 or no creatinine lab value within past year

          -  hospitalized for a stroke, heart attack, or had surgery for blocked arteries in the
             past 3 months,

          -  participating in another interventional trial,

          -  not currently receiving care at the Durham VAMC or the Raleigh CBOC

          -  resident of a nursing home,

          -  hard time seeing type/printing on books, magazines articles, etc.

          -  hard time hearing on the telephone

          -  limited/no access to telephone

          -  plans to move medical care from DVAMC or Raleigh CBOC in next 12 months

          -  CVD care is currently being managed by a clinical pharmacist

          -  HbA1C value in the last 90day &gt; 10% and patient is currently not on an insulin
             regimen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hayden B. Bosworth, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Durham VA Medical Center, Durham, NC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Durham VA Medical Center, Durham, NC</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Melnyk SD, Zullig LL, McCant F, Danus S, Oddone E, Bastian L, Olsen M, Stechuchak KM, Edelman D, Rakley S, Morey M, Bosworth HB. Telemedicine cardiovascular risk reduction in veterans. Am Heart J. 2013 Apr;165(4):501-8. doi: 10.1016/j.ahj.2012.08.005. Epub 2013 Feb 28.</citation>
    <PMID>23537965</PMID>
  </results_reference>
  <results_reference>
    <citation>Zullig LL, Melnyk SD, Stechuchak KM, McCant F, Danus S, Oddone E, Bastian L, Olsen M, Edelman D, Rakley S, Morey M, Bosworth HB. The Cardiovascular Intervention Improvement Telemedicine Study (CITIES): rationale for a tailored behavioral and educational pharmacist-administered intervention for achieving cardiovascular disease risk reduction. Telemed J E Health. 2014 Feb;20(2):135-43. doi: 10.1089/tmj.2013.0145. Epub 2013 Dec 4.</citation>
    <PMID>24303930</PMID>
  </results_reference>
  <results_reference>
    <citation>Goldstein KM, Melnyk SD, Zullig LL, Stechuchak KM, Oddone E, Bastian LA, Rakley S, Olsen MK, Bosworth HB. Heart matters: Gender and racial differences cardiovascular disease risk factor control among veterans. Womens Health Issues. 2014 Sep-Oct;24(5):477-83. doi: 10.1016/j.whi.2014.05.005.</citation>
    <PMID>25213741</PMID>
  </results_reference>
  <results_reference>
    <citation>Zullig LL, Stechuchak KM, Goldstein KM, Olsen MK, McCant FM, Danus S, Crowley MJ, Oddone EZ, Bosworth HB. Patient-reported medication adherence barriers among patients with cardiovascular risk factors. J Manag Care Spec Pharm. 2015 Jun;21(6):479-85.</citation>
    <PMID>26011549</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2010</study_first_submitted>
  <study_first_submitted_qc>June 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2010</study_first_posted>
  <results_first_submitted>March 1, 2016</results_first_submitted>
  <results_first_submitted_qc>April 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 9, 2016</results_first_posted>
  <last_update_submitted>April 7, 2016</last_update_submitted>
  <last_update_submitted_qc>April 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Hyperlipidemia</keyword>
  <keyword>Adherence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pharmacist CVD</title>
          <description>The pharmacist cardiovascular (CVD) intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
        </group>
        <group group_id="P2">
          <title>Education Control</title>
          <description>The education control group - these participants will receive educational material about CVD reduction.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="215"/>
                <participants group_id="P2" count="213"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6 Month f/u</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="196"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="191"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Excluded - did not meet criteria</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pharmacist CVD</title>
          <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
        </group>
        <group group_id="B2">
          <title>Education Control</title>
          <description>The education control group - these participants will receive educational material about CVD reduction.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="215"/>
            <count group_id="B2" value="213"/>
            <count group_id="B3" value="428"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.9" spread="8.4"/>
                    <measurement group_id="B2" value="61.5" spread="8.9"/>
                    <measurement group_id="B3" value="61.2" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Refused/Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="215"/>
                    <measurement group_id="B2" value="213"/>
                    <measurement group_id="B3" value="428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)</title>
        <description>Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and VA Computerized Patient Record System (CPRS) data review). &quot;New cases&quot; of diabetes are allowed to be updated at 6 and 12 months f/u.</description>
        <time_frame>Baseline</time_frame>
        <population>Two out of the 215 participants in the Pharmacist CVD group had missing data due to not having the blood pressure component of the Framingham collected at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacist CVD</title>
            <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Education Control</title>
            <description>The education control group - these participants will receive educational material about CVD reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)</title>
          <description>Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and VA Computerized Patient Record System (CPRS) data review). &quot;New cases&quot; of diabetes are allowed to be updated at 6 and 12 months f/u.</description>
          <population>Two out of the 215 participants in the Pharmacist CVD group had missing data due to not having the blood pressure component of the Framingham collected at baseline.</population>
          <units>% 10 yr Risk</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" spread="18.8"/>
                    <measurement group_id="O2" value="31.6" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Systolic Blood Pressure</title>
        <description>Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews</description>
        <time_frame>Baseline</time_frame>
        <population>One out of the 215 participants in the Pharmacist CVD group did not have blood pressure collected at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacist CVD</title>
            <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Education Control</title>
            <description>The education control group - these participants will receive educational material about CVD reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Systolic Blood Pressure</title>
          <description>Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews</description>
          <population>One out of the 215 participants in the Pharmacist CVD group did not have blood pressure collected at baseline.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.6" spread="18.5"/>
                    <measurement group_id="O2" value="129.7" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Systolic Blood Pressure</title>
        <description>Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews</description>
        <time_frame>6 months</time_frame>
        <population>28 out of the 215 participants in the Pharmacist CVD group and 23 out of the 213 in the Education Control group had missing blood pressure measurement at 6 months due to missing the 6 month interview entirely or blood pressure not collected at the 6 month assessment due to patient arm size exceeding cuff size or interview completed over the phone.</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacist CVD</title>
            <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Education Control</title>
            <description>The education control group - these participants will receive educational material about CVD reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Systolic Blood Pressure</title>
          <description>Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews</description>
          <population>28 out of the 215 participants in the Pharmacist CVD group and 23 out of the 213 in the Education Control group had missing blood pressure measurement at 6 months due to missing the 6 month interview entirely or blood pressure not collected at the 6 month assessment due to patient arm size exceeding cuff size or interview completed over the phone.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.3" spread="16.5"/>
                    <measurement group_id="O2" value="127.7" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 6 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.93</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for gender, diabetes, and smoking status stratification variables</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
            <estimate_desc>Direction of the test of comparison is Pharmacist Intervention minus Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Systolic Blood Pressure</title>
        <description>Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews</description>
        <time_frame>12 months</time_frame>
        <population>36 out of the 215 participants in the Pharmacist CVD group and 30 out of the 213 in the Education Control group had missing blood pressure measurement at 12 mo. due to missing the 12 month interview entirely or blood pressure not collected at the 12 month assessment due to patient arm size exceeding cuff size or interview completed over the phone.</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacist CVD</title>
            <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Education Control</title>
            <description>The education control group - these participants will receive educational material about CVD reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Systolic Blood Pressure</title>
          <description>Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews</description>
          <population>36 out of the 215 participants in the Pharmacist CVD group and 30 out of the 213 in the Education Control group had missing blood pressure measurement at 12 mo. due to missing the 12 month interview entirely or blood pressure not collected at the 12 month assessment due to patient arm size exceeding cuff size or interview completed over the phone.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.5" spread="15.4"/>
                    <measurement group_id="O2" value="126.4" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 12 months.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for gender, diabetes, and smoking status stratification variables</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>4.3</ci_upper_limit>
            <estimate_desc>Direction of the test of comparison is Pharmacist Intervention minus Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Diastolic Blood Pressure</title>
        <description>Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews</description>
        <time_frame>Baseline</time_frame>
        <population>One out of the 215 participants in the Pharmacist CVD group did not have blood pressure collected at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacist CVD</title>
            <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Education Control</title>
            <description>The education control group - these participants will receive educational material about CVD reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Diastolic Blood Pressure</title>
          <description>Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews</description>
          <population>One out of the 215 participants in the Pharmacist CVD group did not have blood pressure collected at baseline.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.8" spread="11.5"/>
                    <measurement group_id="O2" value="75.8" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Diastolic Blood Pressure</title>
        <description>Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews</description>
        <time_frame>6 months</time_frame>
        <population>28 out of the 215 participants in the Pharmacist CVD group and 23 out of the 213 in the Education Control group had missing blood pressure measurement at 6 months due to missing the 6 month interview entirely or blood pressure not collected at the 6 month assessment due to patient arm size exceeding cuff size or interview completed over the phone.</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacist CVD</title>
            <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Education Control</title>
            <description>The education control group - these participants will receive educational material about CVD reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Diastolic Blood Pressure</title>
          <description>Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews</description>
          <population>28 out of the 215 participants in the Pharmacist CVD group and 23 out of the 213 in the Education Control group had missing blood pressure measurement at 6 months due to missing the 6 month interview entirely or blood pressure not collected at the 6 month assessment due to patient arm size exceeding cuff size or interview completed over the phone.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.0" spread="11.0"/>
                    <measurement group_id="O2" value="74.1" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 6 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.91</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for gender, diabetes, and smoking status stratification variables</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
            <estimate_desc>Direction of the test of comparison is Pharmacist Intervention minus Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Diastolic Blood Pressure</title>
        <description>Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews</description>
        <time_frame>12 months</time_frame>
        <population>36 out of the 215 participants in the Pharmacist CVD group and 30 out of the 213 in the Education Control group had missing blood pressure measurement at 12 months due to missing the 12 month interview entirely or blood pressure not collected at the 12 mo. assessment due to patient arm size exceeding cuff size or interview completed over the phone.</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacist CVD</title>
            <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Education Control</title>
            <description>The education control group - these participants will receive educational material about CVD reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Diastolic Blood Pressure</title>
          <description>Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews</description>
          <population>36 out of the 215 participants in the Pharmacist CVD group and 30 out of the 213 in the Education Control group had missing blood pressure measurement at 12 months due to missing the 12 month interview entirely or blood pressure not collected at the 12 mo. assessment due to patient arm size exceeding cuff size or interview completed over the phone.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4" spread="10.3"/>
                    <measurement group_id="O2" value="73.1" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 12 months.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for gender, diabetes, and smoking status stratification variables</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
            <estimate_desc>Direction of the test of comparison is Pharmacist Intervention minus Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)</title>
        <description>Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and CPRS data review). &quot;New cases&quot; of diabetes are allowed to be updated at 6 and 12 months f/u.</description>
        <time_frame>6 months</time_frame>
        <population>29 out of the 215 participants in the Pharmacist CVD group and 24 of the 213 participants in the Education Control group had missing data at 6 months due to entirely missing the 6 month assessment or having missing data on one or more of the Framingham components.</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacist CVD</title>
            <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Education Control</title>
            <description>The education control group - these participants will receive educational material about CVD reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)</title>
          <description>Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and CPRS data review). &quot;New cases&quot; of diabetes are allowed to be updated at 6 and 12 months f/u.</description>
          <population>29 out of the 215 participants in the Pharmacist CVD group and 24 of the 213 participants in the Education Control group had missing data at 6 months due to entirely missing the 6 month assessment or having missing data on one or more of the Framingham components.</population>
          <units>% 10 yr Risk</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" spread="17.2"/>
                    <measurement group_id="O2" value="30.2" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 6 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
            <estimate_desc>Direction of the test of comparison is Pharmacist Intervention minus Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)</title>
        <description>Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and CPRS data review). &quot;New cases&quot; of diabetes are allowed to be updated at 6 and 12 months f/u.</description>
        <time_frame>12 months</time_frame>
        <population>43 out of the 215 participants in the Pharmacist CVD group and 33 of the 213 participants in the Education Control group had missing data at 12 months due to entirely missing the 12 month assessment or having missing data on one or more of the Framingham components.</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacist CVD</title>
            <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Education Control</title>
            <description>The education control group - these participants will receive educational material about CVD reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)</title>
          <description>Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and CPRS data review). &quot;New cases&quot; of diabetes are allowed to be updated at 6 and 12 months f/u.</description>
          <population>43 out of the 215 participants in the Pharmacist CVD group and 33 of the 213 participants in the Education Control group had missing data at 12 months due to entirely missing the 12 month assessment or having missing data on one or more of the Framingham components.</population>
          <units>% 10 yr Risk</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" spread="15.5"/>
                    <measurement group_id="O2" value="28.4" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 12 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.74</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
            <estimate_desc>Direction of the test of comparison is Pharmacist Intervention minus Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medication Non-adherence</title>
        <description>First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.</description>
        <time_frame>Baseline</time_frame>
        <population>5 out of the 215 participants in the Pharmacist CVD group and 2 out of the 213 participants in the Education Control group had missing data for medication non-adherence due to non-response of adherence items collected in the baseline interview.</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacist CVD</title>
            <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Education Control</title>
            <description>The education control group - these participants will receive educational material about CVD reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Non-adherence</title>
          <description>First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.</description>
          <population>5 out of the 215 participants in the Pharmacist CVD group and 2 out of the 213 participants in the Education Control group had missing data for medication non-adherence due to non-response of adherence items collected in the baseline interview.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medication Non-adherence</title>
        <description>First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.</description>
        <time_frame>6 months</time_frame>
        <population>28 out of the 215 participants in the Pharmacist CVD group and 18 out of the 213 participants in the Education Control group had missing data for medication non-adherence due to missing the 6 month assessment or non-response of adherence items collected in the 6 month interview.</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacist CVD</title>
            <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Education Control</title>
            <description>The education control group - these participants will receive educational material about CVD reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Non-adherence</title>
          <description>First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.</description>
          <population>28 out of the 215 participants in the Pharmacist CVD group and 18 out of the 213 participants in the Education Control group had missing data for medication non-adherence due to missing the 6 month assessment or non-response of adherence items collected in the 6 month interview.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 6 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.87</p_value>
            <method>Gen. Est. Equation with a Logit Link</method>
            <method_desc>Method Used Expanded: Generalized Estimating Equation with a Logit Link. Adjusted for gender, diabetes, and smoking status stratification variables</method_desc>
            <param_type>logit-difference (Net)</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
            <estimate_desc>Direction of the test of comparison is Pharmacist Intervention minus Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medication Non-adherence</title>
        <description>First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.</description>
        <time_frame>12 months</time_frame>
        <population>35 out of the 215 participants in the Pharmacist CVD group and 24 out of the 213 participants in the Education Control group had missing data for medication non-adherence due to missing the 12 month assessment or non-response of adherence items collected in the 12 month interview.</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacist CVD</title>
            <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Education Control</title>
            <description>The education control group - these participants will receive educational material about CVD reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Non-adherence</title>
          <description>First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.</description>
          <population>35 out of the 215 participants in the Pharmacist CVD group and 24 out of the 213 participants in the Education Control group had missing data for medication non-adherence due to missing the 12 month assessment or non-response of adherence items collected in the 12 month interview.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 12 months.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Gen. Est. Equation with a Logit Link</method>
            <method_desc>Method Used Expanded: Generalized Estimating Equation with a Logit Link. Adjusted for gender, diabetes, and smoking status stratification variables</method_desc>
            <param_type>logit-difference (Net)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
            <estimate_desc>Direction of the test of comparison is Pharmacist Intervention minus Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cholesterol LDL</title>
        <description>Collected during interview visit by lab personnel</description>
        <time_frame>Baseline</time_frame>
        <population>4 out of the 215 participants in the Pharmacist CVD group and 2 out of the 213 participants in the Education Control group had missing data due to not having cholesterol LDL collected at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacist CVD</title>
            <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Education Control</title>
            <description>The education control group - these participants will receive educational material about CVD reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Cholesterol LDL</title>
          <description>Collected during interview visit by lab personnel</description>
          <population>4 out of the 215 participants in the Pharmacist CVD group and 2 out of the 213 participants in the Education Control group had missing data due to not having cholesterol LDL collected at baseline.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.5" spread="37.3"/>
                    <measurement group_id="O2" value="123.9" spread="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cholesterol LDL</title>
        <description>Collected during interview visit by lab personnel</description>
        <time_frame>6 months</time_frame>
        <population>29 out of the 215 participants in the Pharmacist CVD group and 22 out of the 213 in the Education Control group had missing cholesterol LDL at 6 months due to missing the 6 month interview entirely or not completing the lab assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacist CVD</title>
            <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Education Control</title>
            <description>The education control group - these participants will receive educational material about CVD reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Cholesterol LDL</title>
          <description>Collected during interview visit by lab personnel</description>
          <population>29 out of the 215 participants in the Pharmacist CVD group and 22 out of the 213 in the Education Control group had missing cholesterol LDL at 6 months due to missing the 6 month interview entirely or not completing the lab assessment.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.9" spread="34.9"/>
                    <measurement group_id="O2" value="118.9" spread="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 6 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for gender, diabetes, and smoking status stratification variables</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.3</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
            <estimate_desc>Direction of the test of comparison is Pharmacist Intervention minus Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cholesterol LDL</title>
        <description>Collected during interview visit by lab personnel</description>
        <time_frame>12 months</time_frame>
        <population>34 out of the 215 participants in the Pharmacist CVD group and 27 out of the 213 in the Education Control group had missing cholesterol LDL at 12 months due to missing the 12 month interview entirely or not completing the lab assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacist CVD</title>
            <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Education Control</title>
            <description>The education control group - these participants will receive educational material about CVD reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Cholesterol LDL</title>
          <description>Collected during interview visit by lab personnel</description>
          <population>34 out of the 215 participants in the Pharmacist CVD group and 27 out of the 213 in the Education Control group had missing cholesterol LDL at 12 months due to missing the 12 month interview entirely or not completing the lab assessment.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.4" spread="36.8"/>
                    <measurement group_id="O2" value="115.3" spread="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 12 months.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.79</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for gender, diabetes, and smoking status stratification variables</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>5.0</ci_upper_limit>
            <estimate_desc>Direction of the test of comparison is Pharmacist Intervention minus Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index</title>
        <description>Calculated from vitals (height &amp; weight) obtained during interview</description>
        <time_frame>Baseline</time_frame>
        <population>5 out of the 215 participants in the Pharmacist CVD group and 1 out of the 213 participants in the Education Control group had missing data due weight and/or height not collected at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacist CVD</title>
            <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Education Control</title>
            <description>The education control group - these participants will receive educational material about CVD reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index</title>
          <description>Calculated from vitals (height &amp; weight) obtained during interview</description>
          <population>5 out of the 215 participants in the Pharmacist CVD group and 1 out of the 213 participants in the Education Control group had missing data due weight and/or height not collected at baseline.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9" spread="5.8"/>
                    <measurement group_id="O2" value="31.6" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index</title>
        <description>Calculated from vitals (height &amp; weight) obtained during interview</description>
        <time_frame>6 months</time_frame>
        <population>30 out of the 215 participants in the Pharmacist CVD group and 23 out of the 213 in the Education Control group had missing body mass index at 6 months due to missing the 6 month interview entirely or the interview was completed over the phone, or weight was not obtained at the 6 month interview.</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacist CVD</title>
            <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Education Control</title>
            <description>The education control group - these participants will receive educational material about CVD reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index</title>
          <description>Calculated from vitals (height &amp; weight) obtained during interview</description>
          <population>30 out of the 215 participants in the Pharmacist CVD group and 23 out of the 213 in the Education Control group had missing body mass index at 6 months due to missing the 6 month interview entirely or the interview was completed over the phone, or weight was not obtained at the 6 month interview.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1" spread="6.3"/>
                    <measurement group_id="O2" value="31.5" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 6 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for gender, diabetes, and smoking status stratification variables</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
            <estimate_desc>Direction of the test of comparison is Pharmacist Intervention minus Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index</title>
        <description>Calculated from vitals (height &amp; weight) obtained during interview</description>
        <time_frame>12 months</time_frame>
        <population>39 out of the 215 participants in the Pharmacist CVD group and 31 out of the 213 in the Education Control group had missing body mass index at 12 months due to missing the 12 month interview entirely or the interview was completed over the phone, or weight was not obtained at the 12 month interview.</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacist CVD</title>
            <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Education Control</title>
            <description>The education control group - these participants will receive educational material about CVD reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index</title>
          <description>Calculated from vitals (height &amp; weight) obtained during interview</description>
          <population>39 out of the 215 participants in the Pharmacist CVD group and 31 out of the 213 in the Education Control group had missing body mass index at 12 months due to missing the 12 month interview entirely or the interview was completed over the phone, or weight was not obtained at the 12 month interview.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9" spread="6.0"/>
                    <measurement group_id="O2" value="31.6" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 12 months.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.54</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for gender, diabetes, and smoking status stratification variables</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
            <estimate_desc>Direction of the test of comparison is Pharmacist Intervention minus Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HBA1C in Diabetic Patients</title>
        <description>Lab values collected at interview visit by lab personnel</description>
        <time_frame>Baseline</time_frame>
        <population>4 out of the 85 participants in the Pharmacist CVD group with diabetes at baseline and 2 out of the 86 participants in the Education Control group with diabetes at baseline had missing data due to not having HBA1C collected at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacist CVD</title>
            <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Education Control</title>
            <description>The education control group - these participants will receive educational material about CVD reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>HBA1C in Diabetic Patients</title>
          <description>Lab values collected at interview visit by lab personnel</description>
          <population>4 out of the 85 participants in the Pharmacist CVD group with diabetes at baseline and 2 out of the 86 participants in the Education Control group with diabetes at baseline had missing data due to not having HBA1C collected at baseline.</population>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="2.3"/>
                    <measurement group_id="O2" value="7.6" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HBA1C in Diabetic Patients</title>
        <description>Lab values collected at interview visit by lab personnel</description>
        <time_frame>6 months</time_frame>
        <population>12 out of the 85 participants in the Pharmacist CVD group with diabetes at baseline and 11 out of the 86 participants in the Education Control group with diabetes at baseline had missing HBA1C at 6 months due to missing the 6 month interview entirely or not completing the lab assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacist CVD</title>
            <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Education Control</title>
            <description>The education control group - these participants will receive educational material about CVD reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>HBA1C in Diabetic Patients</title>
          <description>Lab values collected at interview visit by lab personnel</description>
          <population>12 out of the 85 participants in the Pharmacist CVD group with diabetes at baseline and 11 out of the 86 participants in the Education Control group with diabetes at baseline had missing HBA1C at 6 months due to missing the 6 month interview entirely or not completing the lab assessment.</population>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="1.8"/>
                    <measurement group_id="O2" value="7.7" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 6 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for gender and smoking status stratification variables</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
            <estimate_desc>Direction of the test of comparison is Pharmacist Intervention minus Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HBA1C in Diabetic Patients</title>
        <description>Lab values collected at interview visit by lab personnel</description>
        <time_frame>12 months</time_frame>
        <population>14 out of the 85 participants in the Pharmacist CVD group with diabetes at baseline and 15 out of the 86 participants in the Education Control group with diabetes at baseline had missing HBA1C at 6 months due to missing the 6 month interview entirely or not completing the lab assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacist CVD</title>
            <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Education Control</title>
            <description>The education control group - these participants will receive educational material about CVD reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>HBA1C in Diabetic Patients</title>
          <description>Lab values collected at interview visit by lab personnel</description>
          <population>14 out of the 85 participants in the Pharmacist CVD group with diabetes at baseline and 15 out of the 86 participants in the Education Control group with diabetes at baseline had missing HBA1C at 6 months due to missing the 6 month interview entirely or not completing the lab assessment.</population>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="1.8"/>
                    <measurement group_id="O2" value="7.7" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 12 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.72</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for gender and smoking status stratification variables</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
            <estimate_desc>Direction of the test of comparison is Pharmacist Intervention minus Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected through out the study from baseline thru completion.</time_frame>
      <desc>Adverse events information was collected by questionnaire from patients at 6 month and 12 month outcome assessments. Adverse event information was also collected from patients through contact with the Pharmacist interventionist or if during updating of clinical records it was discovered that an adverse event had occurred with a patient.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pharmacist CVD</title>
          <description>The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.</description>
        </group>
        <group group_id="E2">
          <title>Education Control</title>
          <description>The education control group - these participants will receive educational material about CVD reduction.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Non_Cardiac Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Emergecy Room Visit</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Issues</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Emergency room visit</sub_title>
                <counts group_id="E1" events="34" subjects_affected="21" subjects_at_risk="215"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Non_Cardiac Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Orthopedic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Planned Surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Study Safety Protocol</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="215"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Emergency room visit</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Non_Cardiac Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Emergency room visit</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Non_Cardiac Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Emergency room visit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Optometry</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Planned Surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Emergency room visit</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="215"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Gastro_Intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Planned Surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction (non_med SE)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Emergency room visit</sub_title>
                <counts group_id="E1" events="23" subjects_affected="14" subjects_at_risk="215"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Medication Refill</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Neurologic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Non_Cardiac Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Planned Surgery</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Psychological</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Emergency room visit</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="215"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Gastro_Intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="215"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Medication Refill</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Emergency room visit</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Non_Cardiac Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Protocol Deviation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Study Safety Protocol</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Emergency room visit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Emergency room visit</sub_title>
                <counts group_id="E1" events="37" subjects_affected="27" subjects_at_risk="215"/>
                <counts group_id="E2" events="44" subjects_affected="30" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Neurologic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Non_Cardiac Pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Orthopedic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Dermatologic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Emergency room visit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Protocol Deviation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary issues</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Emergency room visit</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Neurologic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Non_Cardiac Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Emergency room visit</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Medication Refill</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Non_Cardiac Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Psychological</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Emergency room visit</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Non_Cardiac Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Planned Surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Non_Cardiac Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Emergency room visit</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Emergency room visit</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="215"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatologic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Emergency room visit</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Emergency room visit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary issues</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Emergency room visit</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Gastro_Intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Orthopedic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Planned Surgery</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="215"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Coronary issues</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Emergency room visit</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Neurologic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Planned Surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hayden B. Bosworth, PhD, Assoc Dir, Durham HSR&amp;D COIN</name_or_title>
      <organization>Veterans Administration HSRD, Durham COIN</organization>
      <phone>919-286-0411 ext 6936</phone>
      <email>hayden.bosworth@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

